Information Provided By:
Fly News Breaks for August 14, 2015
TROV
Aug 14, 2015 | 08:01 EDT
Leerink analyst Dan Leonard started shares of Trovagene with an Outperform rating and $9 price target. The company is an early stage pure play in the cancer liquid biopsy market, which has the potential to be the largest in molecular diagnostics, Leonard tells investors in an analyst note.
News For TROV From the Last 2 Days
There are no results for your query TROV
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.